ArticleESC heart failure2025
Delays in diagnosis and treatment of ATTR cardiac amyloidosis: A real-world data analysis.
Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The Burden of Transthyretin Amyloid Cardiomyopathy on Caregivers and Patients in Japan: A Cross‑Sectional Real‑World Survey.Advances in therapy · 2026Article
- Cardiac Amyloidosis: Pathogenesis, Diagnosis, and Treatment.Deutsches Arzteblatt international · 2026Review
- Pathways for Patients with Transthyretin Amyloid Cardiomyopathy from a District General Hospital Perspective.Journal of cardiovascular development and disease · 2026Article
- Promise and Practical Limits of Multimodal AI for Cardiac Amyloidosis Detection.Circulation. Cardiovascular imaging · 2026Article
- Gender- and sex-dependent variations in heart failure and cardiomyopathies: a review of the literature.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Sex Differences in Hospitalizations in the 6 Months Before a Diagnosis of Transthyretin Amyloid Cardiomyopathy.JACC. Advances · 2026Article
- Incidental Cardiac Uptake onDiseases (Basel, Switzerland) · 2026Review
- Sex-specific differences in cardiac transthyretin amyloidosis: addressing the diagnostic gap in women.European heart journal open · 2026Article
- Living with Transthyretin amyloid cardiomyopathy from a patient perspective.BMC cardiovascular disorders · 2025Article
- Real-World Clinical Evidence With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy - A Contemporary Review.Circulation reports · 2025Review
- Delays in diagnosis and treatment of ATTR cardiac amyloidosis: A real-world data analysis.ESC heart failure · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS AND
backgroundCardiac amyloidosis leads to functional cardiac impairment and heart failure. Transthyretin amyloid cardiomyopathy (ATTR-CM) is the most common form. After initial suspicion, diagnosis involves imaging techniques, biopsy and genetic tests, prompting transthyretin stabilizer therapy to slow disease progression. The study aims to assess delays in diagnosis in ATTR-CM patients.
methodsPatients with ATTR-CM receiving transthyretin stabilizer therapy at the West German Amyloidosis Center (01/2018-12/2023) were included. Clinical, laboratory, and imaging data were analysed. Diagnostic timelines were compared across two periods (2018-2020 and 2021-2023).
resultsAfter screening 254 patients, 154 were included in the analysis. ATTRwt was the most common form (96.8%). The median age was 80 (76-83) years, 87% were male and 46.6% were NYHA class ≥III. Time to diagnosis decreased from 398 to 277 days in the second period (P < 0.001). The median duration from diagnosis to stabilizer therapy was 84 (44-160) days, reducing from 111 (55-237) days in the first period to 57 (36-102) days in the second period (P < 0.001). Patients diagnosed in the first period had lower LVEF (P < 0.001) and more advanced NAC stages (P = 0.004). More women were diagnosed in the second period (P = 0.010).
conclusionATTR-CM is associated with diagnostic delays from initial suspicion to therapy initiation. While diagnostic and treatment timelines have improved, enhanced awareness, supraregional networks, specialized centres and focused education are essential to improve diagnosis and outcomes. Increasing awareness has led to patients being diagnosed at earlier disease stages, underscoring the potential to positively impact patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.